Cystadenocarcinoma of the parotid: case report of a BRAF inhibitor treatment

BACKGROUND: Mutations of the proto-oncogene BRAF have been described in many cancers. Mutated BRAF causes overactive downstream signaling via MEK and ERK leading to excessive cell proliferation and survival. Their identification is of real interest because specific inhibitors have been developed. ME...

Descripción completa

Detalles Bibliográficos
Autores principales: Boyrie, Sabrina, Fauquet, Isabelle, Rives, Michel, Genebes, Caroline, Delord, Jean-Pierre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3872282/
https://www.ncbi.nlm.nih.gov/pubmed/24386625
http://dx.doi.org/10.1186/2193-1801-2-679
_version_ 1782296937648619520
author Boyrie, Sabrina
Fauquet, Isabelle
Rives, Michel
Genebes, Caroline
Delord, Jean-Pierre
author_facet Boyrie, Sabrina
Fauquet, Isabelle
Rives, Michel
Genebes, Caroline
Delord, Jean-Pierre
author_sort Boyrie, Sabrina
collection PubMed
description BACKGROUND: Mutations of the proto-oncogene BRAF have been described in many cancers. Mutated BRAF causes overactive downstream signaling via MEK and ERK leading to excessive cell proliferation and survival. Their identification is of real interest because specific inhibitors have been developed. METHODS AND RESULTS: We report the case of a patient with an aggressive cystadenocarcinoma of the parotid with synchronous metastases. Cisplatine/5FU chemotherapy associated with palliative radiation therapy was used first without any efficency nor clinical improvement. A molecular analysis revealed a BRAF mutation. A compassionate treatment with a BRAF inhibitor showed very good results from the first month. The patient reported real improvement in clinical condition and pain. From an imaging point of view, computed tomographies reported a complete response on mediastinal lymph nodes and regeneration on bone metastases. CONCLUSION: This first report suggests BRAF could be a potent oncogenic driver in salivary gland carcinoma. It deserves a multicenter academic prospective trial to provide proof of efficiency with BRAF inhibitors in theses tumors.
format Online
Article
Text
id pubmed-3872282
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-38722822014-01-02 Cystadenocarcinoma of the parotid: case report of a BRAF inhibitor treatment Boyrie, Sabrina Fauquet, Isabelle Rives, Michel Genebes, Caroline Delord, Jean-Pierre Springerplus Case Study BACKGROUND: Mutations of the proto-oncogene BRAF have been described in many cancers. Mutated BRAF causes overactive downstream signaling via MEK and ERK leading to excessive cell proliferation and survival. Their identification is of real interest because specific inhibitors have been developed. METHODS AND RESULTS: We report the case of a patient with an aggressive cystadenocarcinoma of the parotid with synchronous metastases. Cisplatine/5FU chemotherapy associated with palliative radiation therapy was used first without any efficency nor clinical improvement. A molecular analysis revealed a BRAF mutation. A compassionate treatment with a BRAF inhibitor showed very good results from the first month. The patient reported real improvement in clinical condition and pain. From an imaging point of view, computed tomographies reported a complete response on mediastinal lymph nodes and regeneration on bone metastases. CONCLUSION: This first report suggests BRAF could be a potent oncogenic driver in salivary gland carcinoma. It deserves a multicenter academic prospective trial to provide proof of efficiency with BRAF inhibitors in theses tumors. Springer International Publishing 2013-12-18 /pmc/articles/PMC3872282/ /pubmed/24386625 http://dx.doi.org/10.1186/2193-1801-2-679 Text en © Boyrie et al.; licensee Springer. 2013 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Study
Boyrie, Sabrina
Fauquet, Isabelle
Rives, Michel
Genebes, Caroline
Delord, Jean-Pierre
Cystadenocarcinoma of the parotid: case report of a BRAF inhibitor treatment
title Cystadenocarcinoma of the parotid: case report of a BRAF inhibitor treatment
title_full Cystadenocarcinoma of the parotid: case report of a BRAF inhibitor treatment
title_fullStr Cystadenocarcinoma of the parotid: case report of a BRAF inhibitor treatment
title_full_unstemmed Cystadenocarcinoma of the parotid: case report of a BRAF inhibitor treatment
title_short Cystadenocarcinoma of the parotid: case report of a BRAF inhibitor treatment
title_sort cystadenocarcinoma of the parotid: case report of a braf inhibitor treatment
topic Case Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3872282/
https://www.ncbi.nlm.nih.gov/pubmed/24386625
http://dx.doi.org/10.1186/2193-1801-2-679
work_keys_str_mv AT boyriesabrina cystadenocarcinomaoftheparotidcasereportofabrafinhibitortreatment
AT fauquetisabelle cystadenocarcinomaoftheparotidcasereportofabrafinhibitortreatment
AT rivesmichel cystadenocarcinomaoftheparotidcasereportofabrafinhibitortreatment
AT genebescaroline cystadenocarcinomaoftheparotidcasereportofabrafinhibitortreatment
AT delordjeanpierre cystadenocarcinomaoftheparotidcasereportofabrafinhibitortreatment